“Novo Nordisk heard loud and clear the impact to the 15,000 Australians living with diabetes who depended on FIASP, if FIASP was no longer available on the PBS. We are pleased that patients can continue accessing this treatment on the PBS,” said Cem Ozenc, corporate vice president and general manager of Novo Nordisk Oceania.
Patients win reprieve with Novo Nordisk listing a new form of insulin aspart
September 17, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
US FDA grants conditional approval to the brand name of Dimerix's DMX-200
September 25, 2023 - - Australian Biotech -
Budget outcome confirms double-digit growth for pharmaceutical spend
September 25, 2023 - - Latest News -
These major processes related to public health programs can not continue in this way
September 25, 2023 - - Latest News -
Hospital pharmacy launches new professional recognition program
September 25, 2023 - - Latest News -
The 'Week in Review' Podcast - 22 September
September 22, 2023 - - Podcast -
National and Labour commit to addressing Pharmac's fiscal 'cliff'
September 22, 2023 - - Latest News -
Moderna launches 'Welcome to the mRNAge' brand campaign
September 22, 2023 - - Latest News